AGARWAL, RAJESH KUMAR,BETTS, WILLIAM L,HENSHILWOOD, JAMES A,KIANG, YUAN-HON,POST, NOAH
申请号：
NZ58975605
公开号：
NZ589756A
申请日:
2005.12.20
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is a method for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate comprising exposing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride to water to form (R)-8-chloro-1-methy1-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate. Crystalline forms I, II and III are disclosed. Forms I and II are anhydrous, hydroscopic forms, both of which readily convert to Form III, a hemihydrate, upon exposure to moisture. The forms are characterised according to their powder-X-ray diffraction (PXRD) spectra, differential scanning calorimetry (DSC), dynamic vapour sorption (DVS) and thermogravimetric analysis (TGA). The compounds are useful for treating obesity, decreasing food intake, inducing satiety, controlling weight gain, central nervous system disorders, diabetes insipidus and sleep apnoea (apnea). The compounds are also useful for treating depression, atypical depression, a bipolar disorder, an anxiety disorder, an obsessive-compulsive disorder, a social phobia or panic state, a sleep disorder, sexual dysfunction, a psychosis, schizophrenia, migraine or a condition associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, a personality disorder, an age-related behavioural disorder, a behavioural disorder associated with dementia, an organic mental disorder, a mental disorder in childhood, aggressivity, an age-related memory disorder, chronic fatigue syndrome, drug or alcohol addiction, obesity, bulimia, anorexia nervosa, or premenstrual tension.
